Once epithelial neoplasms such as carcinomas of the breast and prostate become metastatic and develop resistance to hormonal therapy and chemotherapy, there are no effective options for the control of the disease. As a novel approach to treat these and other malignancies, we constructed a fusion protein called an Icon, composed of factor VII (fVII) as the targeting domain and the Fc region of IgG as the effector domain that activates a cytolytic immune attack against cells that bind the Icon. The Icon binds with exceptional affinity and specificity to tissue factor (TF), the natural receptor for fVII that is expressed on endothelial cells of the vasculature in all solid tumors but not in normal tissues. TF also is expressed on malignant tumor cells, providing a target for both the tumor vasculature and tumor cells. Previous data in a human tumor xenograft model showed that intratumoral injections of an adenoviral vector encoding the Icon can induce regressions of the injected tumor as well as tumors elsewhere in the body that were not injected. We now propose the following specific aims which take advantage of the projects and cores of the Vascular Therapy Program Project Grant in order to further prepare the Icon for cancer treatment.
Specific Aim # 1: Use of intravital microscopy to optimize the dose, schedule and optimal mode of delivery of the icon for therapy: intratumoral injection of the Icon vector vs tail vein injection of the Icon protein (intravital microscopy provides short term data on the selectivity of binding of the Icon to tumor vasculature and response of the tumor vascular endothelial cells as well as the tumor cells);
Specific Aim #2 : Use of the human tumor xenograft model for the optimization of the dose, schedule and optimal mode of delivery of the Icon for therapy: intratumoral injection of the Icon vector vs tail vein injection of the Icon protein (the xenograft model provides long term tumor response data as well as information on selectivity of binding of the Icon to the tumor vasculature);
Specific Aim #3 : Use of transgenic mouse models of spontaneous cancer and human Tissue Factor to test the safety, selectivity and efficacy of the Icon for suppressing growth of established disease which has developed over months (rather than over days as is the case with the intravital microscopy and xenograph models) as well as its spread (metastasis) to other organs;
Specific Aim #4 : Study of the effect of Icon therapy combined with other tumor vascular targeting treatments on the tumor vasculature and the tumor cells as well the study of the changes which occur in the Icon after its introduction into the bloodstream before binding to TF, and the processing of the TF/fVII complex after it is formed;
and Specific Aim #5 : a Phase I clinical trial of the Icon. If these proposed studies show that the Icon is safe and effective in the neoplasms proposed for study, it may be possible to use the Icon for the many other types of cancers that depend on a neovasculature for continued growth.
| Oh, Phil; Testa, Jacqueline E; Borgstrom, Per et al. (2014) In vivo proteomic imaging analysis of caveolae reveals pumping system to penetrate solid tumors. Nat Med 20:1062-8 |
| Sawada, Junko; Urakami, Takeo; Li, Fangfei et al. (2012) Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels. Cancer Cell 22:235-49 |
| Chrastina, Adrian; Schnitzer, Jan E (2012) Laser-targeted photosensitizer-induced lung injury: noninvasive rat model of pulmonary infarction. Exp Lung Res 38:1-8 |
| Weis, Sara M; Cheresh, David A (2011) ?V integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med 1:a006478 |
| Shields, D J; Murphy, E A; Desgrosellier, J S et al. (2011) Oncogenic Ras/Src cooperativity in pancreatic neoplasia. Oncogene 30:2123-34 |
| Murphy, Eric A; Majeti, Bharat K; Mukthavaram, Rajesh et al. (2011) Targeted nanogels: a versatile platform for drug delivery to tumors. Mol Cancer Ther 10:972-82 |
| Chrastina, Adrian; Massey, Kerri A; Schnitzer, Jan E (2011) Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 3:421-37 |
| Mielgo, Ainhoa; Seguin, Laetitia; Huang, Miller et al. (2011) A MEK-independent role for CRAF in mitosis and tumor progression. Nat Med 17:1641-5 |
| Koziol, James A (2010) Comments on the rank product method for analyzing replicated experiments. FEBS Lett 584:941-4 |
| Anand, Sudarshan; Majeti, Bharat K; Acevedo, Lisette M et al. (2010) MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med 16:909-14 |
Showing the most recent 10 out of 38 publications
